PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31327131-0 2019 Effects of resveratrol on VEGF & HIF1 genes expression in granulosa cells in the angiogenesis pathway and laboratory parameters of polycystic ovary syndrome: a triple-blind randomized clinical trial. Resveratrol 11-22 vascular endothelial growth factor A Homo sapiens 26-30 31125919-0 2019 Resveratrol-delivery vehicle with anti-VEGF activity carried to human retinal pigmented epithelial cells exposed to high-glucose induced conditions. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 39-43 31327131-2 2019 Therefore, this study was conducted to describe the effect of resveratrol on the angiogenesis pathway, for management of PCOS through assessing VEGF, HIF1 gene expression, and laboratory parameters. Resveratrol 62-73 vascular endothelial growth factor A Homo sapiens 144-148 31327131-8 2019 The results showed a reduction in the expression of VEGF & HIF1 genes under the effect of resveratrol in the granulosa cells (P = 0.0001). Resveratrol 94-105 vascular endothelial growth factor A Homo sapiens 52-56 31327131-10 2019 CONCLUSIONS: Based on the results, resveratrol may improve some outcomes of PCOS patients, probably through changing the serum levels of some sex hormones and expression of VEGF & HIF1 genes in the angiogenesis pathway of granulosa cells. Resveratrol 35-46 vascular endothelial growth factor A Homo sapiens 173-177 30525561-4 2019 In human umbilical vein endothelial cells (HUVECs), compared with a VEGF-induced group, resveratrol, at a high concentration, suppressed VEGF-mediated endothelial cell proliferation, cell migration, cell invasion, and tube formation by 80 +- 9.01%, 140 +- 3.78%, 110 +- 7.51%, and 120 +- 10.26%, respectively. Resveratrol 88-99 vascular endothelial growth factor A Homo sapiens 68-72 30525561-4 2019 In human umbilical vein endothelial cells (HUVECs), compared with a VEGF-induced group, resveratrol, at a high concentration, suppressed VEGF-mediated endothelial cell proliferation, cell migration, cell invasion, and tube formation by 80 +- 9.01%, 140 +- 3.78%, 110 +- 7.51%, and 120 +- 10.26%, respectively. Resveratrol 88-99 vascular endothelial growth factor A Homo sapiens 137-141 30525561-0 2019 Binding of Resveratrol to Vascular Endothelial Growth Factor Suppresses Angiogenesis by Inhibiting the Receptor Signaling. Resveratrol 11-22 vascular endothelial growth factor A Homo sapiens 26-60 30525561-1 2019 Resveratrol is a polyphenol commonly found in plants and food health products, such as grape and red wine, and was identified for its binding to vascular endothelial growth factor (VEGF) by using HerboChips screening. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 145-179 30525561-6 2019 In signaling cascades, application of resveratrol in HUVECs reduced the VEGF-triggered VEGF receptor 2 phosphorylation and c-Jun N-terminal kinase phosphorylation. Resveratrol 38-49 vascular endothelial growth factor A Homo sapiens 72-76 30525561-1 2019 Resveratrol is a polyphenol commonly found in plants and food health products, such as grape and red wine, and was identified for its binding to vascular endothelial growth factor (VEGF) by using HerboChips screening. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 181-185 30525561-3 2019 Several lines of evidence gave support to the inhibitory activities of resveratrol in VEGF-triggered angiogenesis. Resveratrol 71-82 vascular endothelial growth factor A Homo sapiens 86-90 30525561-6 2019 In signaling cascades, application of resveratrol in HUVECs reduced the VEGF-triggered VEGF receptor 2 phosphorylation and c-Jun N-terminal kinase phosphorylation. Resveratrol 38-49 vascular endothelial growth factor A Homo sapiens 87-91 30525561-7 2019 Moreover, the VEGF-mediated phosphorylations of endothelial nitric oxide synthase, protein kinase B, and extracellular signal-regulated kinase were obviously decreased by (3 +- 0.37)-, (2 +- 0.27)- and (6 +- 0.23)-fold, respectively, in the presence of resveratrol at high concentration. Resveratrol 253-264 vascular endothelial growth factor A Homo sapiens 14-18 30525561-8 2019 Parallelly, the VEGF-induced reactive oxygen species formation was significantly decreased by 50 +- 7.88% to 120 +- 14.82% under resveratrol treatment. Resveratrol 129-140 vascular endothelial growth factor A Homo sapiens 16-20 30525561-9 2019 Thus, our results provided support to the antiangiogenic roles of resveratrol, as well as its related signaling mechanisms, in attenuating the VEGF-mediated responses. Resveratrol 66-77 vascular endothelial growth factor A Homo sapiens 143-147 27906095-0 2016 Resveratrol and acetyl-resveratrol modulate activity of VEGF and IL-8 in ovarian cancer cell aggregates via attenuation of the NF-kappaB protein. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 56-60 30013318-12 2018 Resveratrol inhibits VEGF expression in human adult RPE cells and limits the development of proliferative vitreoretinopathy, by attenuating transforming growth factor-beta2-induced wound closure and cell migration. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 21-25 28656256-0 2017 HS-1793, a resveratrol analogue, downregulates the expression of hypoxia-induced HIF-1 and VEGF and inhibits tumor growth of human breast cancer cells in a nude mouse xenograft model. Resveratrol 11-22 vascular endothelial growth factor A Homo sapiens 91-95 28356937-4 2017 The results indicated that resveratrol treatment may suppress growth, induce apoptosis, and decrease AngII, AT1R, VEGF and COX-2 levels in renal carcinoma ACHN and A498 cells. Resveratrol 27-38 vascular endothelial growth factor A Homo sapiens 114-118 28356937-5 2017 In addition, resveratrol-induced cell growth suppression and apoptosis were reversed when co-culturing with AT1R or VEGF. Resveratrol 13-24 vascular endothelial growth factor A Homo sapiens 116-120 28356937-6 2017 Thus, resveratrol may suppress renal carcinoma cell proliferation and induce apoptosis via an AT1R/VEGF pathway. Resveratrol 6-17 vascular endothelial growth factor A Homo sapiens 99-103 28302032-8 2017 Resveratrol treatment also led to VEGF downregulation in FLIP cells. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 34-38 30044005-0 2018 Resveratrol inhibits VEGF-induced angiogenesis in human endothelial cells associated with suppression of aerobic glycolysis via modulation of PKM2 nuclear translocation. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 21-25 30044005-3 2018 In the present study, we first report that resveratrol (RST), which has been intensively studied in glucose metabolism of various cancer cells, has a profound inhibitory effect on tube formation and migration via suppression of glycolysis in human umbilical vein endothelial cells (HUVECs) induced by vascular endothelial growth factor (VEGF). Resveratrol 43-54 vascular endothelial growth factor A Homo sapiens 301-335 30044005-3 2018 In the present study, we first report that resveratrol (RST), which has been intensively studied in glucose metabolism of various cancer cells, has a profound inhibitory effect on tube formation and migration via suppression of glycolysis in human umbilical vein endothelial cells (HUVECs) induced by vascular endothelial growth factor (VEGF). Resveratrol 43-54 vascular endothelial growth factor A Homo sapiens 337-341 30044005-3 2018 In the present study, we first report that resveratrol (RST), which has been intensively studied in glucose metabolism of various cancer cells, has a profound inhibitory effect on tube formation and migration via suppression of glycolysis in human umbilical vein endothelial cells (HUVECs) induced by vascular endothelial growth factor (VEGF). Resveratrol 56-59 vascular endothelial growth factor A Homo sapiens 301-335 30044005-3 2018 In the present study, we first report that resveratrol (RST), which has been intensively studied in glucose metabolism of various cancer cells, has a profound inhibitory effect on tube formation and migration via suppression of glycolysis in human umbilical vein endothelial cells (HUVECs) induced by vascular endothelial growth factor (VEGF). Resveratrol 56-59 vascular endothelial growth factor A Homo sapiens 337-341 29363137-10 2018 HUVECs treated with resveratrol exhibited significantly higher expression of mRNAs encoding SIRT1, VEGF and VE-cadherin (P = 0.0019, 0.00005 and 0.0045, respectively) compared with controls, but sirtinol inhibited such expression. Resveratrol 20-31 vascular endothelial growth factor A Homo sapiens 99-103 30496679-0 2017 Synthesis and Biological Evaluation of Imines Structurally Related to Resveratrol as Dual Inhibitors of VEGF Protein Secretion and hTERT Gene Expression. Resveratrol 70-81 vascular endothelial growth factor A Homo sapiens 104-108 27906095-12 2016 CONCLUSIONS: The results suggest that resveratrol and its derivative acetyl-resveratrol may inhibit in vitro 3D cell growth of certain subtypes of ovarian cancer, and growth restriction may be associated with the secretion of VEGF under the control of the NF-kappaB protein. Resveratrol 38-49 vascular endothelial growth factor A Homo sapiens 226-230 26706021-4 2016 In addition, resveratrol inhibits expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor, explaining its effective action against cancer. Resveratrol 13-24 vascular endothelial growth factor A Homo sapiens 84-118 26687643-0 2016 Resveratrol reduces IL-6 and VEGF secretion from co-cultured A549 lung cancer cells and adipose-derived mesenchymal stem cells. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 29-33 27323060-9 2016 In summary, we conclude that resveratrol inhibits the proliferation of MCF-7 cells by TTP upregulation, which is associated with downregulation of COX-2 and VEGF and upregulation of iNOS. Resveratrol 29-40 vascular endothelial growth factor A Homo sapiens 157-161 27145432-2 2016 Therefore, we herein examined the effects of resveratrol on M2 macrophage activation and differentiation, and those of resveratrol-treated condition medium (CM) in M2 macrophages on vascular endothelial cell growth factor (VEGF)-C-induced migration, invasion, and tube formation by human lymphatic endothelial cells (HLECs). Resveratrol 119-130 vascular endothelial growth factor A Homo sapiens 182-221 26950104-7 2016 In addition to this, resveratrol was shown to possess anti-VEGF effects and to inhibit the proliferation and migration of vascular endothelial cells. Resveratrol 21-32 vascular endothelial growth factor A Homo sapiens 59-63 27323060-7 2016 In addition, the expression of COX-2 and VEGF were significantly suppressed by resveratrol while that of inducible nitric oxide synthase (iNOS) was upregulated. Resveratrol 79-90 vascular endothelial growth factor A Homo sapiens 41-45 27323060-8 2016 Lastly, the effects of resveratrol on both MCF-7 proliferation and expression of COX-2, VEGF, and iNOS were significantly inhibited by TTP knockdown, indicating that TTP mediates the anticancer properties of resveratrol. Resveratrol 23-34 vascular endothelial growth factor A Homo sapiens 88-92 24319332-6 2013 The effect of resveratrol on hypoxia-induced vascular endothelial growth factor (VEGF) release was analyzed with enzyme-linked immunosorbent assay. Resveratrol 14-25 vascular endothelial growth factor A Homo sapiens 45-79 26174951-4 2015 Furthermore, RSV down-regulated VEGFR2 phosphorylation and activation induced by VEGF in endothelial cells via SIRT1. Resveratrol 13-16 vascular endothelial growth factor A Homo sapiens 32-36 26174951-5 2015 Thus, the inhibitory effect of RSV on the HIF-1alpha/VEGF/VEGFR2 signaling axis is mediated, at least in part, through SIRT1. Resveratrol 31-34 vascular endothelial growth factor A Homo sapiens 53-57 26402726-0 2015 Inhibitory effect of cytotoxic stilbenes related to resveratrol on the expression of the VEGF, hTERT and c-Myc genes. Resveratrol 52-63 vascular endothelial growth factor A Homo sapiens 89-93 26174951-0 2015 SIRT1 mediated inhibition of VEGF/VEGFR2 signaling by Resveratrol and its relevance to choroidal neovascularization. Resveratrol 54-65 vascular endothelial growth factor A Homo sapiens 29-33 26174951-3 2015 Western blot and ELISA assay showed that RSV inhibited hypoxia-inducible factor (HIF)-1alpha accumulation and VEGF secretion induced by cobalt chloride (CoCl2) through SIRT1 in human retinal pigment epithelial (hRPE) cells. Resveratrol 41-44 vascular endothelial growth factor A Homo sapiens 110-114 26254104-5 2015 Resveratrol further decreased the deleterious action of PA on gene expression of vascularization factors (TNFalpha, VEGF-A, SDF1alpha, PECAM-1, VEGFR2, Tie2 and CXCR4) and improved CAC motility. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 116-122 26446654-1 2015 PURPOSE: To investigate the effects of resveratrol on the expression of hypoxia-inducible factor 1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) in human adult retinal pigment epithelial (ARPE-19) cells, and on experimental choroidal neovascularization (CNV) in mice. Resveratrol 39-50 vascular endothelial growth factor A Homo sapiens 121-155 26446654-1 2015 PURPOSE: To investigate the effects of resveratrol on the expression of hypoxia-inducible factor 1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) in human adult retinal pigment epithelial (ARPE-19) cells, and on experimental choroidal neovascularization (CNV) in mice. Resveratrol 39-50 vascular endothelial growth factor A Homo sapiens 157-161 26446654-6 2015 RESULTS: In ARPE-19 cells, resveratrol significantly inhibited HIF-1alpha and VEGF in a dose-dependent manner, by blocking the PI3K/Akt/mTOR signaling pathway and by promoting proteasomal HIF-1alpha degradation. Resveratrol 27-38 vascular endothelial growth factor A Homo sapiens 78-82 25815440-0 2015 Resveratrol suppresses vascular endothelial growth factor secretion via inhibition of CXC-chemokine receptor 4 expression in ARPE-19 cells. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 23-57 25815440-1 2015 The present study characterizes the effects of resveratrol (Res) on vascular endothelial growth factor (VEGF) secretion in retinal pigment epithelial (RPE) cells. Resveratrol 47-58 vascular endothelial growth factor A Homo sapiens 68-102 25815440-1 2015 The present study characterizes the effects of resveratrol (Res) on vascular endothelial growth factor (VEGF) secretion in retinal pigment epithelial (RPE) cells. Resveratrol 47-58 vascular endothelial growth factor A Homo sapiens 104-108 26617640-9 2015 Resveratrol, acetyl-resveratrol, and polydatin suppressed the secretion of VEGF in a dose-dependant fashion. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 75-79 24729934-0 2014 Resveratrol Suppresses Expression of VEGF by Human Retinal Pigment Epithelial Cells: Potential Nutraceutical for Age-related Macular Degeneration. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 37-41 24729934-4 2014 Here, we report the inhibitory actions of resveratrol (RSV) on inflammatory cytokine, TGF-beta and hypoxia induced VEGF secretion by human retinal pigment epithelial cells (HRPE). Resveratrol 42-53 vascular endothelial growth factor A Homo sapiens 115-119 24729934-4 2014 Here, we report the inhibitory actions of resveratrol (RSV) on inflammatory cytokine, TGF-beta and hypoxia induced VEGF secretion by human retinal pigment epithelial cells (HRPE). Resveratrol 55-58 vascular endothelial growth factor A Homo sapiens 115-119 24729934-8 2014 RSV, in a dose dependent (10-50 uM) manner, suppressed VEGF-A and VEGF-C secretion induced by inflammatory cytokines significantly. Resveratrol 0-3 vascular endothelial growth factor A Homo sapiens 55-61 24729934-9 2014 RT-PCR analysis indicated that effects of RSV on VEGF secretion were possibly due to decreased mRNA levels. Resveratrol 42-45 vascular endothelial growth factor A Homo sapiens 49-53 24729934-10 2014 TGF-beta and cobalt chloride (hypoxia mimic) also upregulated HRPE cell production of VEGF-A, and this was inhibited by RSV. Resveratrol 120-123 vascular endothelial growth factor A Homo sapiens 86-92 24729934-13 2014 These results demonstrate that RSV can suppress VEGF secretion induced by inflammatory cytokines, TGF-beta and hypoxia. Resveratrol 31-34 vascular endothelial growth factor A Homo sapiens 48-52 24901151-0 2014 Resveratrol inhibits VEGF gene expression and proliferation of hepatocarcinoma cells. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 21-25 24901151-6 2014 CONCLUSIONS: Our results suggest that Res can significantly inhibit the proliferation of HepG2 cells and exerts an anti-tumor effect by repressing the expression of VEGF gene. Resveratrol 38-41 vascular endothelial growth factor A Homo sapiens 165-169 24100602-0 2013 A novel resveratrol analogue, HS-1793, inhibits hypoxia-induced HIF-1alpha and VEGF expression, and migration in human prostate cancer cells. Resveratrol 8-19 vascular endothelial growth factor A Homo sapiens 79-83 24100602-3 2013 This study investigated the effects of a novel analogue of resveratrol, HS-1793, on the expression of HIF-1alpha and vascular endothelial growth factor (VEGF) in PC-3 human prostate cancer cells. Resveratrol 59-70 vascular endothelial growth factor A Homo sapiens 117-151 24100602-3 2013 This study investigated the effects of a novel analogue of resveratrol, HS-1793, on the expression of HIF-1alpha and vascular endothelial growth factor (VEGF) in PC-3 human prostate cancer cells. Resveratrol 59-70 vascular endothelial growth factor A Homo sapiens 153-157 24319332-6 2013 The effect of resveratrol on hypoxia-induced vascular endothelial growth factor (VEGF) release was analyzed with enzyme-linked immunosorbent assay. Resveratrol 14-25 vascular endothelial growth factor A Homo sapiens 81-85 24319332-9 2013 Hypoxia-induced VEGF release (30.9+-2.6 pg/ml) was inhibited in a dose-dependent fashion by 2, 4, 6, 8, 10, and 12 mug/ml resveratrol to 12.4+-2.1, 11.0+-1.9, 10.3+-3.0, 7.5+-1.9, 5.5+-2.0, and 5.5+-2.3 pg/ml, respectively. Resveratrol 122-133 vascular endothelial growth factor A Homo sapiens 16-20 24319332-13 2013 Resveratrol, a nutritional supplement and inhibitor of CVECs, may be a useful adjunct to current anti-VEGF therapy in wet age-related macular degeneration. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 102-106 22451299-0 2012 Resveratrol and its synthetic derivatives exert opposite effects on mesothelial cell-dependent angiogenesis via modulating secretion of VEGF and IL-8/CXCL8. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 136-140 23205110-0 2012 Effects of resveratrol on vascular endothelial growth factor expression in osteosarcoma cells and cell proliferation. Resveratrol 11-22 vascular endothelial growth factor A Homo sapiens 26-60 23205110-1 2012 The aim of the current study was to investigate the effects of resveratrol (Res) on vascular endothelial growth factor (VEGF) expression and cell proliferation in the human osteosarcoma cell line U20S. Resveratrol 63-74 vascular endothelial growth factor A Homo sapiens 84-118 23205110-1 2012 The aim of the current study was to investigate the effects of resveratrol (Res) on vascular endothelial growth factor (VEGF) expression and cell proliferation in the human osteosarcoma cell line U20S. Resveratrol 63-74 vascular endothelial growth factor A Homo sapiens 120-124 23536519-5 2013 Moreover, resveratrol downregulated the expressions of leptin and c-Myc, and decreased the content of vascular endothelial growth factor. Resveratrol 10-21 vascular endothelial growth factor A Homo sapiens 102-136 22178239-7 2012 Secretion was reduced by the naturally-occurring compounds, (-)-epigallocatechin gallate (EGCG) and 3,4",5-trihydroxystilbene (resveratrol), which we have previously demonstrated to also suppress VEGF secretion in endometrial tumour tissue. Resveratrol 100-125 vascular endothelial growth factor A Homo sapiens 196-200 22178239-7 2012 Secretion was reduced by the naturally-occurring compounds, (-)-epigallocatechin gallate (EGCG) and 3,4",5-trihydroxystilbene (resveratrol), which we have previously demonstrated to also suppress VEGF secretion in endometrial tumour tissue. Resveratrol 127-138 vascular endothelial growth factor A Homo sapiens 196-200 20927579-0 2010 Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture. Resveratrol 27-38 vascular endothelial growth factor A Homo sapiens 61-65 21962734-8 2011 Similarly, treatment with Resveratrol significantly attenuated AAA expansion, vessel wall macrophage infiltration and MMP-9, VEGF, and TNFalpha expression, compared with AAA from Et-OH group. Resveratrol 26-37 vascular endothelial growth factor A Homo sapiens 125-129 21687947-0 2011 Inhibitory effect of resveratrol on the expression of the VEGF gene and proliferation in renal cancer cells. Resveratrol 21-32 vascular endothelial growth factor A Homo sapiens 58-62 21687947-2 2011 In this study, we investigated the effects of Res on the expression of the vascular endothelial growth factor (VEGF) gene and on cell proliferation in human renal cancer (786-0) cells. Resveratrol 46-49 vascular endothelial growth factor A Homo sapiens 75-109 21687947-2 2011 In this study, we investigated the effects of Res on the expression of the vascular endothelial growth factor (VEGF) gene and on cell proliferation in human renal cancer (786-0) cells. Resveratrol 46-49 vascular endothelial growth factor A Homo sapiens 111-115 20927579-3 2010 We hypothesized that the anti-angiogenic activity of resveratrol may be caused by modulation of tumor cell release of thrombospondin-1 (TSP1) and vascular endothelial growth factor (VEGF) into the extracellular matrix, leading to vascular endothelial cell (VEC) apoptosis. Resveratrol 53-64 vascular endothelial growth factor A Homo sapiens 146-180 20927579-3 2010 We hypothesized that the anti-angiogenic activity of resveratrol may be caused by modulation of tumor cell release of thrombospondin-1 (TSP1) and vascular endothelial growth factor (VEGF) into the extracellular matrix, leading to vascular endothelial cell (VEC) apoptosis. Resveratrol 53-64 vascular endothelial growth factor A Homo sapiens 182-186 20801891-8 2010 Dexamethasone and resveratrol inhibited concentration-dependently TNFalpha-induced IL-8, GM-CSF, and VEGF release. Resveratrol 18-29 vascular endothelial growth factor A Homo sapiens 101-105 20671276-7 2010 RESULTS: At sub-cytotoxic levels, ISL (10 muM), EGCG (50 muM), and Rst (10 muM) suppressed HUVEC proliferation and migration under VEGF (20 ng/mL) stimulation in our scratch-wound model. Resveratrol 67-70 vascular endothelial growth factor A Homo sapiens 131-135 21410066-0 2010 Resveratrol inhibits VEGF expression of human hepatocellular carcinoma cells through a NF-kappa B-mediated mechanism. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 21-25 20339855-0 2010 Effects of oxysterols on cell viability, inflammatory cytokines, VEGF, and reactive oxygen species production on human retinal cells: cytoprotective effects and prevention of VEGF secretion by resveratrol. Resveratrol 193-204 vascular endothelial growth factor A Homo sapiens 175-179 20696143-4 2010 We observed that resveratrol was able to modulate the expression of VEGF and the formation of vascular network in a biphasic pattern. Resveratrol 17-28 vascular endothelial growth factor A Homo sapiens 68-72 20696143-5 2010 While resveratrol at low concentrations, from 1 to 10muM, up-regulated the expression of VEGF and promoted angiogenesis, it had opposite effect at high concentrations (20muM and higher). Resveratrol 6-17 vascular endothelial growth factor A Homo sapiens 89-93 21410066-2 2010 The aim of the present study was to determine the inhibitory effect of resveratrol on vascular endothelial growth factor (VEGF) expression and angiogenesis in hepatocellular carcinoma (HCC) and to explore its mechanism. Resveratrol 71-82 vascular endothelial growth factor A Homo sapiens 86-120 21410066-2 2010 The aim of the present study was to determine the inhibitory effect of resveratrol on vascular endothelial growth factor (VEGF) expression and angiogenesis in hepatocellular carcinoma (HCC) and to explore its mechanism. Resveratrol 71-82 vascular endothelial growth factor A Homo sapiens 122-126 21410066-6 2010 RESULTS: We found that VEGF protein and mRNA expressions in the cells treated with resveratrol were significantly decreased. Resveratrol 83-94 vascular endothelial growth factor A Homo sapiens 23-27 21410066-10 2010 CONCLUSIONS: The inhibitory effect of resveratrol on VEGF activity may occur partly through suppression of the activation of NF-kappa B in HepG2 cells. Resveratrol 38-49 vascular endothelial growth factor A Homo sapiens 53-57 20507262-0 2010 Effects of resveratrol on expression of vascular endothelial growth factor in human gingival fibroblasts stimulated by periodontal pathogens. Resveratrol 11-22 vascular endothelial growth factor A Homo sapiens 40-74 20578705-9 2010 Incubation of ARPE-19 cells with 33 mM glucose in the presence of 0-10 microM trans-resveratrol dose-dependently inhibited VEGF, TGF-beta1, COX-2, IL-6, and IL-8 accumulation, PKCbeta activation, and Cx43 degradation and enhanced GJIC. Resveratrol 78-95 vascular endothelial growth factor A Homo sapiens 123-127 19908231-7 2010 Resveratrol inhibited the proliferation of 4 different human PaCa cell lines, synergized the apoptotic effects of gemcitabine, inhibited the constitutive activation of NF-kappaB and expression of bcl-2, bcl-xL, COX-2, cyclin D1 MMP-9 and VEGF. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 238-242 20507262-1 2010 OBJECTIVE: To investigate the effects of resveratrol, a naturally occurring polyphenol, on the expression of vascular endothelial growth factor (VEGF) in human gingival fibroblast culture in response to vesicles and outer membrane proteins from periodontopathic bacteria. Resveratrol 41-52 vascular endothelial growth factor A Homo sapiens 109-143 20507262-1 2010 OBJECTIVE: To investigate the effects of resveratrol, a naturally occurring polyphenol, on the expression of vascular endothelial growth factor (VEGF) in human gingival fibroblast culture in response to vesicles and outer membrane proteins from periodontopathic bacteria. Resveratrol 41-52 vascular endothelial growth factor A Homo sapiens 145-149 20507262-3 2010 In human gingival fibroblast cultures treated with or without resveratrol, VEGF production was evaluated by means of enzyme-linked immunosorbent assay and VEGF mRNA expression by means of reverse transcription polymerase chain reaction analysis. Resveratrol 62-73 vascular endothelial growth factor A Homo sapiens 75-79 20507262-5 2010 RESULTS: Resveratrol significantly inhibited the increased production of VEGF by human gingival fibroblasts in response to vesicles and outer membrane proteins from periodontopathic bacteria, as shown by the detection of these proteins and their mRNA in vitro. Resveratrol 9-20 vascular endothelial growth factor A Homo sapiens 73-77 20507262-7 2010 CONCLUSIONS: Overall, these findings suggest that resveratrol inhibits production of VEGF by stimulated human gingival fibroblasts and can inhibit vascular permeability, suggesting a therapeutic role for it in pathogenic bacteria-induced periodontal inflammation. Resveratrol 50-61 vascular endothelial growth factor A Homo sapiens 85-89 20012470-0 2010 FOXO transcription factors and VEGF neutralizing antibody enhance antiangiogenic effects of resveratrol. Resveratrol 92-103 vascular endothelial growth factor A Homo sapiens 31-35 20021702-4 2010 Resveratrol and quercetin (0.1-1 microm) increased eNOS and VEGF mRNA expression particularly in the absence of H2O2 (50 microm) and decreased H2O2-induced ET-1 mRNA expression (P < 0.001 for polyphenol x H2O2 interactions). Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 60-64 20012470-9 2010 Finally, VEGF neutralizing antibody enhanced the anti-proliferative and anti-angiogenic effects of resveratrol. Resveratrol 99-110 vascular endothelial growth factor A Homo sapiens 9-13 19321194-0 2009 Regulation of Vascular Endothelial Growth Factor in endometrial tumour cells by resveratrol and EGCG. Resveratrol 80-91 vascular endothelial growth factor A Homo sapiens 14-48 20606295-0 2010 Resveratrol inhibits angiogenic response of cultured endothelial F-2 cells to vascular endothelial growth factor, but not to basic fibroblast growth factor. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 78-112 20606295-1 2010 Resveratrol, a natural polyphenol in grapes, is known to prevent the cardiovascular diseases and to exert the antiangiogenic effect in in vivo models with vascular endothelial growth factor (VEGF) or basic fibroblast growth factor (bFGF). Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 155-189 20606295-1 2010 Resveratrol, a natural polyphenol in grapes, is known to prevent the cardiovascular diseases and to exert the antiangiogenic effect in in vivo models with vascular endothelial growth factor (VEGF) or basic fibroblast growth factor (bFGF). Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 191-195 20606295-4 2010 Resveratrol dose-dependently prevented the VEGF-induced tubule formation, but failed to inhibit the angiogenic response to bFGF. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 43-47 20606295-5 2010 We next examined whether the inhibition of nitric oxide (NO) production is linked to the antiangiogenic effect of resveratrol on VEGF-stimulated F-2 cells, because NO plays a crucial role in VEGF-induced tubular network formation. Resveratrol 114-125 vascular endothelial growth factor A Homo sapiens 129-133 20606295-6 2010 NO production was increased by VEGF, but not by bFGF, and resveratrol inhibited VEGF-stimulated NO production. Resveratrol 58-69 vascular endothelial growth factor A Homo sapiens 80-84 20606295-12 2010 These results suggest that resveratrol exerts the inhibitory effects on VEGF- and bFGF-induced angiogenesis through different mechanisms including inhibition of NO production in VEGF-stimulated endothelial cells and inhibition of COX-2 induction in bFGF-stimulated fibroblasts. Resveratrol 27-38 vascular endothelial growth factor A Homo sapiens 72-77 20606295-12 2010 These results suggest that resveratrol exerts the inhibitory effects on VEGF- and bFGF-induced angiogenesis through different mechanisms including inhibition of NO production in VEGF-stimulated endothelial cells and inhibition of COX-2 induction in bFGF-stimulated fibroblasts. Resveratrol 27-38 vascular endothelial growth factor A Homo sapiens 72-76 19881294-3 2009 In contrast, pretreatment with resveratrol at low concentrations caused a significant decrease in vascular endothelial growth factor (VEGF)-stimulated NO production. Resveratrol 31-42 vascular endothelial growth factor A Homo sapiens 98-132 19881294-3 2009 In contrast, pretreatment with resveratrol at low concentrations caused a significant decrease in vascular endothelial growth factor (VEGF)-stimulated NO production. Resveratrol 31-42 vascular endothelial growth factor A Homo sapiens 134-138 19881294-5 2009 However, resveratrol markedly suppressed VEGF-induced eNOS phosphorylation. Resveratrol 9-20 vascular endothelial growth factor A Homo sapiens 41-45 19881294-8 2009 These results indicate that resveratrol stimulates NO production by a Ca(2+)-dependent mechanism and reduces VEGF-stimulated NO production by impairing a Ca(2+)-independent mechanism in endothelial F-2 cells. Resveratrol 28-39 vascular endothelial growth factor A Homo sapiens 109-113 21191486-11 2010 At high dose, resveratrol not only hinders tumor growth but also inhibits the synthesis of RNA, DNA and protein, causes structural chromosome aberrations, chromatin breaks, chromatin exchanges, weak aneuploidy, higher S-phase arrest, blocks cell proliferation, decreases wound healing, endothelial cell growth by fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor, and angiogenesis in healthy tissue cells leading to cell death. Resveratrol 14-25 vascular endothelial growth factor A Homo sapiens 352-386 20443159-7 2009 Growing or metastasizing carcinomas are inhibited by resveratrol through prevention of angiogenesis by inhibiting VEGF and matrix metalloproteases. Resveratrol 53-64 vascular endothelial growth factor A Homo sapiens 114-118 19321194-1 2009 OBJECTIVE: Our purpose was to establish whether resveratrol and (-)-epigallocatechin-3-gallate (EGCG), two compounds extracted from food, would reduce the amount of Vascular Endothelial Growth Factor (VEGF) secreted into the supernatants of cultured endometrial cancer cells. Resveratrol 48-59 vascular endothelial growth factor A Homo sapiens 165-199 19321194-1 2009 OBJECTIVE: Our purpose was to establish whether resveratrol and (-)-epigallocatechin-3-gallate (EGCG), two compounds extracted from food, would reduce the amount of Vascular Endothelial Growth Factor (VEGF) secreted into the supernatants of cultured endometrial cancer cells. Resveratrol 48-59 vascular endothelial growth factor A Homo sapiens 201-205 19321194-8 2009 In contrast, treatment with either resveratrol or EGCG significantly reduced secretion of VEGF. Resveratrol 35-46 vascular endothelial growth factor A Homo sapiens 90-94 19321194-10 2009 CONCLUSION: Both resveratrol and EGCG induced significant reductions in the amount of VEGF secreted into the supernatant of cultured endometrial cancer cells. Resveratrol 17-28 vascular endothelial growth factor A Homo sapiens 86-90 19889203-8 2009 RESULTS: Treatment with curcumin and resveratrol suppressed NF-kappaB-regulated gene products involved in inflammation (cyclooxygenase-2, matrix metalloproteinase (MMP)-3, MMP-9, vascular endothelial growth factor), inhibited apoptosis (Bcl-2, Bcl-xL, and TNF-alpha receptor-associated factor 1) and prevented activation of caspase-3. Resveratrol 37-48 vascular endothelial growth factor A Homo sapiens 179-213 18606398-6 2008 In this study we provide experimental evidence that resveratrol inhibits the expression of VEGF, MMP-3, MMP-9 and COX-2 in human articular chondrocytes stimulated with the pro-inflammatory cytokine IL-1beta. Resveratrol 52-63 vascular endothelial growth factor A Homo sapiens 91-95 19571580-8 2009 Quenching of intracellular ROS by resveratrol inhibits PlGF- and VEGF-dependent induction of MAP kinase phosphorylation. Resveratrol 34-45 vascular endothelial growth factor A Homo sapiens 65-69 17935668-13 2007 Furthermore, decreased levels of VEGF, bFGF, MMP-2 and MMP-9 mRNA from cells treated with various concentrations of resveratrol confirmed its antiangiogenic action at the level of gene expression. Resveratrol 116-127 vascular endothelial growth factor A Homo sapiens 33-37 18674879-5 2008 Hypoxia and iron chelator 2,2"-dipyridyl treatment can stimulate the invasion and migration enhancement of Lovo cells, while resveratrol exhibited substantial resistance on the metastasis potential stimulation by inhibiting the mRNA expression of VEGF and MMP-9 in colon carcinoma cells under normoxia and hypoxia, reducing HIF-1 alpha protein expression under hypoxia. Resveratrol 125-136 vascular endothelial growth factor A Homo sapiens 247-251 17880362-14 2007 In addition, resveratrol increased vascular endothelial growth factor production and further induced vasculogenesis in vitro. Resveratrol 13-24 vascular endothelial growth factor A Homo sapiens 35-69 17919812-0 2007 Hypoxia enhances LPA-induced HIF-1alpha and VEGF expression: their inhibition by resveratrol. Resveratrol 81-92 vascular endothelial growth factor A Homo sapiens 44-48 17919812-4 2007 These increases in HIF-1alpha and VEGF expression are dramatically attenuated by resveratrol. Resveratrol 81-92 vascular endothelial growth factor A Homo sapiens 34-38 17919812-5 2007 The underlying mechanism of inhibition of HIF-1alpha expression by resveratrol seems to be associated with both inactivation of p42/p44 MAPK and p70S6K, as well as enhanced degradation of HIF-1alpha protein, resulting in profound decrease in VEGF expression and cell migration. Resveratrol 67-78 vascular endothelial growth factor A Homo sapiens 242-246 17919812-6 2007 Collectively, these results show that LPA under hypoxic condition enhances cell migration through the sequential induction of HIF-1alpha and VEGF, and that this enhancement is efficiently blocked by resveratrol. Resveratrol 199-210 vascular endothelial growth factor A Homo sapiens 141-145 17935668-12 2007 Resveratrol inhibited VEGF and bFGF protein expression in a dose and time dependent manner. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 22-26 17935668-14 2007 CONCLUSIONS: Resveratrol inhibits multiple myeloma angiogenesis by regulating expression and secretion of VEGF, bFGF, MMP-2 and MMP-9. Resveratrol 13-24 vascular endothelial growth factor A Homo sapiens 106-110 18060622-0 2007 Resveratrol inhibits the secretion of vascular endothelial growth factor and subsequent proliferation in human leukemia U937 cells. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 38-72 18060622-1 2007 This study examined the effect of resveratrol on the secretion of vascular endothelial growth factor (VEGF) and subsequent proliferation of human leukemia U937 cells, and explored the mechanisms involved. Resveratrol 34-45 vascular endothelial growth factor A Homo sapiens 66-100 18060622-1 2007 This study examined the effect of resveratrol on the secretion of vascular endothelial growth factor (VEGF) and subsequent proliferation of human leukemia U937 cells, and explored the mechanisms involved. Resveratrol 34-45 vascular endothelial growth factor A Homo sapiens 102-106 18060622-10 2007 Resveratrol inhibited the secretion of VEGF in U937 cells. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 39-43 18060622-12 2007 It was concluded that resveratrol could down-regulate the secretion of VEGF, induce apoptosis and suppress the proliferation of U937 cells. Resveratrol 22-33 vascular endothelial growth factor A Homo sapiens 71-75 16356836-4 2006 In vitro we found a significant increase in apoptosis in resveratrol-treated MDA-MB-231 cells in addition to significantly reduced extracellular levels of VEGF. Resveratrol 57-68 vascular endothelial growth factor A Homo sapiens 155-159 16490592-8 2006 Resveratrol also down-regulated the expression of NF-kappaB-regulated gene products by Western blot analysis, gelatin zymography, and enzyme-linked immunosorbent assay, including interleukin-6, Bcl-2, Bcl-xL, XIAP, c-IAP, vascular endothelial growth factor (VEGF), and matrix metalloproteinase-9 (MMP-9), which modulates an array of signals controlling cellular survival and proliferation and tumor promotion. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 222-256 16490592-8 2006 Resveratrol also down-regulated the expression of NF-kappaB-regulated gene products by Western blot analysis, gelatin zymography, and enzyme-linked immunosorbent assay, including interleukin-6, Bcl-2, Bcl-xL, XIAP, c-IAP, vascular endothelial growth factor (VEGF), and matrix metalloproteinase-9 (MMP-9), which modulates an array of signals controlling cellular survival and proliferation and tumor promotion. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 258-262 16198371-4 2005 Human coronary arteriolar endothelial cells exposed to resveratrol or Trx-1 on Matrigel demonstrated significantly accelerated tubular morphogenesis with induction of HO-1 and VEGF expression. Resveratrol 55-66 vascular endothelial growth factor A Homo sapiens 176-180 15041740-9 2004 The expression of vascular endothelial growth factor in the glioma cells and the proliferation of ECV304 cells were inhibited by resveratrol in a concentration-dependent manner. Resveratrol 129-140 vascular endothelial growth factor A Homo sapiens 18-52 15297429-5 2004 Resveratrol also greatly inhibited VEGF expression. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 35-39 15297429-6 2004 Mechanistically, we demonstrated that resveratrol inhibited HIF-1alpha and VEGF expression through multiple mechanisms. Resveratrol 38-49 vascular endothelial growth factor A Homo sapiens 75-79 15297429-10 2004 Our data suggested that resveratrol may inhibit human ovarian cancer progression and angiogenesis by inhibiting HIF-1alpha and VEGF expression and thus provide a novel potential mechanism for the anticancer action of resveratrol. Resveratrol 24-35 vascular endothelial growth factor A Homo sapiens 127-131 15297429-10 2004 Our data suggested that resveratrol may inhibit human ovarian cancer progression and angiogenesis by inhibiting HIF-1alpha and VEGF expression and thus provide a novel potential mechanism for the anticancer action of resveratrol. Resveratrol 217-228 vascular endothelial growth factor A Homo sapiens 127-131 16227395-0 2005 Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 89-93 16227395-2 2005 In this study, we investigated the effect of resveratrol, a natural product commonly found in grapes and various other fruits, on hypoxia-induced HIF-1alpha protein accumulation and vascular endothelial growth factor (VEGF) expression in human tongue squamous cell carcinomas and hepatoma cells. Resveratrol 45-56 vascular endothelial growth factor A Homo sapiens 182-216 16227395-4 2005 Pretreatment of cells with resveratrol significantly reduced hypoxia-induced VEGF promoter activities and VEGF expression at both mRNA and protein levels. Resveratrol 27-38 vascular endothelial growth factor A Homo sapiens 77-81 16227395-4 2005 Pretreatment of cells with resveratrol significantly reduced hypoxia-induced VEGF promoter activities and VEGF expression at both mRNA and protein levels. Resveratrol 27-38 vascular endothelial growth factor A Homo sapiens 106-110 16227395-6 2005 In addition, resveratrol remarkably inhibited hypoxia-mediated activation of extracellular signal-regulated kinase 1/2 and Akt, leading to a marked decrease in hypoxia-induced HIF-1alpha protein accumulation and VEGF transcriptional activation. Resveratrol 13-24 vascular endothelial growth factor A Homo sapiens 212-216 16227395-8 2005 These data suggested that HIF-1alpha/VEGF could be a promising drug target for resveratrol in the development of an effective chemopreventive and anticancer therapy in human cancers. Resveratrol 79-90 vascular endothelial growth factor A Homo sapiens 37-41 15517885-4 2004 Resveratrol has been shown to suppress the activation of several transcription factors, including NF-kappaB, AP-1 and Egr-1; to inhibit protein kinases including IkappaBalpha kinase, JNK, MAPK, Akt, PKC, PKD and casein kinase II; and to down-regulate products of genes such as COX-2, 5-LOX, VEGF, IL-1, IL-6, IL-8, AR and PSA. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 291-295 11425488-5 2001 This study provides first evidence showing that natural extracts such as grape seed proanthocyanidin extract containing 5000 ppm resveratrol (GSPE) facilitates oxidant-induced VEGF expression in keratinocytes. Resveratrol 129-140 vascular endothelial growth factor A Homo sapiens 176-180 14573751-0 2003 Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation. Resveratrol 73-84 vascular endothelial growth factor A Homo sapiens 14-48 14573751-2 2003 Here, we investigate the detailed mechanism by which resveratrol inhibits vascular endothelial growth factor (VEGF)-induced angiogenic effects in human umbilical endothelial cells (HUVECs). Resveratrol 53-64 vascular endothelial growth factor A Homo sapiens 74-108 14573751-2 2003 Here, we investigate the detailed mechanism by which resveratrol inhibits vascular endothelial growth factor (VEGF)-induced angiogenic effects in human umbilical endothelial cells (HUVECs). Resveratrol 53-64 vascular endothelial growth factor A Homo sapiens 110-114 14573751-3 2003 Exposure of HUVECs to 1 to 2.5 muM resveratrol significantly blocked VEGF-mediated migration and tube formation but not cell proliferation. Resveratrol 35-46 vascular endothelial growth factor A Homo sapiens 69-73 12074976-14 2002 A combination of grape seed proanthocyanidin extract and resveratrol facilitates inducible VEGF expression, a key element supporting wound angiogenesis. Resveratrol 57-68 vascular endothelial growth factor A Homo sapiens 91-95 14573751-5 2003 Of interest, resveratrol, at the dose of 1 or 2.5 muM, effectively abrogated VEGF-mediated tyrosine phosphorylation of vascular endothelial (VE)-cadherin and its complex partner, beta-catenin. Resveratrol 13-24 vascular endothelial growth factor A Homo sapiens 77-81 14573751-7 2003 Src kinase assay showed that VEGF-induced endogenous Src kinase activation was strongly inhibited by 1 and 2.5 muM resveratrol. Resveratrol 115-126 vascular endothelial growth factor A Homo sapiens 29-33 14573751-11 2003 Flow cytometric analysis showed that VEGF stimulated an evident increase of peroxide, which was strongly attenuated by resveratrol. Resveratrol 119-130 vascular endothelial growth factor A Homo sapiens 37-41 14573751-13 2003 Together, our data suggest that resveratrol inhibition of VEGF-induced angiogenesis was mediated by disruption of ROS-dependent Src kinase activation and the subsequent VE-cadherin tyrosine phosphorylation. Resveratrol 32-43 vascular endothelial growth factor A Homo sapiens 58-62 12374620-6 2002 Previously we have reported that a grape seed proanthycyanidin extract containing 5000 ppm resveratrol (GSPE) potently upregulates oxidant and tumor necrosis factor-alpha inducible VEGF expression in human keratinocytes (Free Radic. Resveratrol 91-102 vascular endothelial growth factor A Homo sapiens 181-185 11158990-6 2001 The nonselective cyclooxygenase (COX) inhibitor indomethacin (5 microM) and the selective COX-2 inhibitor NS-398 (5 microM) potentiated the stimulatory effect of VEGF, whereas the selective COX-1 inhibitor resveratrol (5 microM) was without effect. Resveratrol 206-217 vascular endothelial growth factor A Homo sapiens 162-166 34934403-7 2022 Resveratrol suppresses the production of hypoxia-inducible factor-1alpha and vascular endothelial growth factor proteins. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 77-111 35415913-0 2022 Resveratrol may ameliorate rheumatoid arthritis via the STAT3/HIF-1/VEGF molecular pathway. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 68-72 34751046-1 2021 PURPOSE: To investigate the adjunct efficacy and safety of vitamin supplements, including resveratrol, in patients with diabetic macular edema (DME) treated with intravitreal anti-vascular endothelial factor (anti-VEGF) agents. Resveratrol 90-101 vascular endothelial growth factor A Homo sapiens 214-218 34176441-6 2021 Resveratrol downregulated angiogenin, VEGF, RGS5, CD105, and the cell adhesion molecules ITGA5, ITGB1, and CD44 expressions to inhibit the vascular normalization, metastasis, adhesion, and migration of CAL-27 cells. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 38-42 34205419-4 2021 We highlight that Resvega , a combination of omega-3 fatty acids with an antioxidant, resveratrol, inhibits VEGF-A secretion in vitro by disrupting the dissociation of the VEGF-R2/Cav-1 complex into rafts and subsequently preventing MAPK activation. Resveratrol 86-97 vascular endothelial growth factor A Homo sapiens 108-114 34129726-0 2021 Resveratrol reduces drug resistance of SCLC cells by suppressing the inflammatory microenvironment and the STAT3/VEGF pathway. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 113-117 35415913-5 2022 We suggest this hypothesis that Resveratrol (RSV) may act its anti-rheumatoid arthritis effects by STAT3/HIF-1/VEGF pathway for these reasons: (A) RSV exhibits anti-inflammatory properties, which can reduce inflammation of joints, (B) RSV reduces the level of pro-inflammatory cytokines accumulation, (C) RSV can suppress the expression of HIF-1 and VEGF genes and also inhibits STAT3 function. Resveratrol 32-43 vascular endothelial growth factor A Homo sapiens 111-115 35415913-5 2022 We suggest this hypothesis that Resveratrol (RSV) may act its anti-rheumatoid arthritis effects by STAT3/HIF-1/VEGF pathway for these reasons: (A) RSV exhibits anti-inflammatory properties, which can reduce inflammation of joints, (B) RSV reduces the level of pro-inflammatory cytokines accumulation, (C) RSV can suppress the expression of HIF-1 and VEGF genes and also inhibits STAT3 function. Resveratrol 32-43 vascular endothelial growth factor A Homo sapiens 350-354 35415913-5 2022 We suggest this hypothesis that Resveratrol (RSV) may act its anti-rheumatoid arthritis effects by STAT3/HIF-1/VEGF pathway for these reasons: (A) RSV exhibits anti-inflammatory properties, which can reduce inflammation of joints, (B) RSV reduces the level of pro-inflammatory cytokines accumulation, (C) RSV can suppress the expression of HIF-1 and VEGF genes and also inhibits STAT3 function. Resveratrol 45-48 vascular endothelial growth factor A Homo sapiens 111-115 35415913-5 2022 We suggest this hypothesis that Resveratrol (RSV) may act its anti-rheumatoid arthritis effects by STAT3/HIF-1/VEGF pathway for these reasons: (A) RSV exhibits anti-inflammatory properties, which can reduce inflammation of joints, (B) RSV reduces the level of pro-inflammatory cytokines accumulation, (C) RSV can suppress the expression of HIF-1 and VEGF genes and also inhibits STAT3 function. Resveratrol 147-150 vascular endothelial growth factor A Homo sapiens 111-115 33387724-0 2021 A randomized exploratory trial to assess the effects of resveratrol on VEGF and TNF-alpha 2 expression in endometriosis women. Resveratrol 56-67 vascular endothelial growth factor A Homo sapiens 71-75 35415913-7 2022 Thus RSV can act as an anti-RA drug in this way, (D) According to previous findings, angiogenesis plays one of the main roles in RA and RSV inhibits angiogenesis via STAT3/HIF-1/VEGF pathway. Resveratrol 5-8 vascular endothelial growth factor A Homo sapiens 178-182 35415913-7 2022 Thus RSV can act as an anti-RA drug in this way, (D) According to previous findings, angiogenesis plays one of the main roles in RA and RSV inhibits angiogenesis via STAT3/HIF-1/VEGF pathway. Resveratrol 136-139 vascular endothelial growth factor A Homo sapiens 178-182 35415913-14 2022 We recommend the theory that RSV has therapeutic effects on RA via STAT3/HIF-1/VEGF molecular pathway and we investigate more information about it in this article. Resveratrol 29-32 vascular endothelial growth factor A Homo sapiens 79-83 35415913-15 2022 As this paper shows pharmacological and clinical documents about RSV in RA, it considers that RSV can ameliorate RA in STAT3/HIF-1/VEGF molecular pathway. Resveratrol 65-68 vascular endothelial growth factor A Homo sapiens 131-135 35415913-15 2022 As this paper shows pharmacological and clinical documents about RSV in RA, it considers that RSV can ameliorate RA in STAT3/HIF-1/VEGF molecular pathway. Resveratrol 94-97 vascular endothelial growth factor A Homo sapiens 131-135 35300418-11 2022 In agreement with these results, reduced expression of vascular endothelial growth factor (VEGF) mRNA was observed in MGCs with Rapamycin, whereas pigment epithelium-derived factor (PEDF) mRNA levels significantly increased in MGCs incubated with Resveratrol. Resveratrol 247-258 vascular endothelial growth factor A Homo sapiens 55-89 33723310-0 2021 The effects of resveratrol on the expression of VEGF, TGF-beta, and MMP-9 in endometrial stromal cells of women with endometriosis. Resveratrol 15-26 vascular endothelial growth factor A Homo sapiens 48-52 33723310-2 2021 The present study has evaluated the effect of resveratrol on the expression of vascular endothelial growth factor (VEGF), transforming growth factor-beta (TGF-beta) and matrix metalloproteinase-9 (MMP-9) as factors related to endometriosis progression. Resveratrol 46-57 vascular endothelial growth factor A Homo sapiens 79-113 33723310-2 2021 The present study has evaluated the effect of resveratrol on the expression of vascular endothelial growth factor (VEGF), transforming growth factor-beta (TGF-beta) and matrix metalloproteinase-9 (MMP-9) as factors related to endometriosis progression. Resveratrol 46-57 vascular endothelial growth factor A Homo sapiens 115-119 33723310-5 2021 Also, resveratrol treatment decreased the gene and protein expression of VEGF and MMP-9 in EuESCs, EESCs and CESCs (P < 0.05 to < 0.01 and P < 0.05 to < 0.01 respectively) and gene and protein expression of TGF-beta in EESCs and EuESCs (P < 0.05 to < 0.01). Resveratrol 6-17 vascular endothelial growth factor A Homo sapiens 73-77 33723310-6 2021 The effect of resveratrol in reduction of VEGF gene expression was statistically more noticeable in EESCs compared to EuESCs and CESCs (P < 0.05). Resveratrol 14-25 vascular endothelial growth factor A Homo sapiens 42-46 33723310-7 2021 According to the findings, resveratrol may ameliorate endometriosis progression through reducing the expression of VEGF, TGF-beta, and MMP-9 in endometrial stromal cells (ESCs). Resveratrol 27-38 vascular endothelial growth factor A Homo sapiens 115-119 33387724-3 2021 In this study, we assessed the effects of resveratrol on vascular endothelial growth factor (VEGF) and tumor necrosis factor alpha (TNF-alpha) expression in the eutopic endometrium of infertile patients with endometriosis within the window of implantation as a randomized exploratory trial. Resveratrol 42-53 vascular endothelial growth factor A Homo sapiens 57-91 33387724-3 2021 In this study, we assessed the effects of resveratrol on vascular endothelial growth factor (VEGF) and tumor necrosis factor alpha (TNF-alpha) expression in the eutopic endometrium of infertile patients with endometriosis within the window of implantation as a randomized exploratory trial. Resveratrol 42-53 vascular endothelial growth factor A Homo sapiens 93-97 33387724-9 2021 It seems resveratrol may improve the endometrium of endometriosis patients in window of implantation period by modifying the expression of VEGF and TNF-alpha but further investigations are needed to reveal the potential role of this compound. Resveratrol 9-20 vascular endothelial growth factor A Homo sapiens 139-143 33184983-6 2021 Likewise, resveratrol also mitigated Ang-1 and VEGF signals. Resveratrol 10-21 vascular endothelial growth factor A Homo sapiens 47-51 32273826-7 2020 In contrast, resveratrol significantly increased the levels of SIRT1 and mtDNA copy number, but reduced VEGF production in normoxia. Resveratrol 13-24 vascular endothelial growth factor A Homo sapiens 104-108 33260857-2 2020 Previous studies have shown that resveratrol, a polyphenol of grapevines, can prevent VEGF secretion induced by stress from retinal cells. Resveratrol 33-44 vascular endothelial growth factor A Homo sapiens 86-90 33085055-3 2020 Resveratrol, a naturally occurring antioxidant and anti-inflammatory polyphenol, was loaded in PLGA polymeric nanoparticles to study their sustained release property and effectiveness in reducing expression of VEGF protein in vitro. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 210-214 33085055-11 2020 The results showed successful development of resveratrol-loaded nanoparticles which may be used for neovascular AMD treatment alone or in combination with anti-VEGF agents. Resveratrol 45-56 vascular endothelial growth factor A Homo sapiens 160-164 32824997-0 2020 Piceatannol, a Natural Analog of Resveratrol, Exerts Anti-angiogenic Efficiencies by Blockage of Vascular Endothelial Growth Factor Binding to Its Receptor. Resveratrol 33-44 vascular endothelial growth factor A Homo sapiens 97-131 32482454-6 2020 This insult induced apoptosis and decreased viability during 72 h. The presence of resveratrol significantly attenuated HIF-1alpha and ROS production, reduced apoptosis, promoted the VEGF secretion, and increased the insulin and C-peptide secretion. Resveratrol 83-94 vascular endothelial growth factor A Homo sapiens 183-187 32273826-8 2020 Resveratrol could recover CoCl2-suppressed SIRT1 and mtDNA expression and antagonize CoCl2-induced VEGF production. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 99-103 32273826-10 2020 Resveratrol significantly suppressed the production of the CoCl2-induced HIF-1alpha and VEGF proteins. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 88-92 32273826-11 2020 Conclusion: These results suggest that resveratrol improves mitochondrial quantity by activating the SIRT1/PGC-1alpha pathway and inhibits VEGF induction through HIF-1alpha under hypoxic conditions. Resveratrol 39-50 vascular endothelial growth factor A Homo sapiens 139-143 31978799-6 2020 CONCLUSION: Resveratrol-preprocessed BMSCs can activate the PI3K/AKT signaling pathway in pancreatic cells and HUVECs through paracrine release of VEGFA; thus, achieving the therapeutic effect of resisting apoptosis of pancreatic cells and promoting regeneration of damaged blood vessels. Resveratrol 12-23 vascular endothelial growth factor A Homo sapiens 147-152 32111491-3 2020 Resveratrol triggers apoptosis of activated T cells and suppresses tumor necrosis factor-alpha (TNF-alpha), interleukin-17 (IL-17) and other pro-inflammatory molecules and inhibits expression of hypoxia inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) that may explain its anti-inflammatory actions. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 244-278 32111491-3 2020 Resveratrol triggers apoptosis of activated T cells and suppresses tumor necrosis factor-alpha (TNF-alpha), interleukin-17 (IL-17) and other pro-inflammatory molecules and inhibits expression of hypoxia inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) that may explain its anti-inflammatory actions. Resveratrol 0-11 vascular endothelial growth factor A Homo sapiens 280-284